Bridgefront Capital’s Atara Biotherapeutics ATRA Stock Holding History

Bridgefront Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-492	Closed	-$177K	–	602
2021 Q1	$177K	Buy	+492	New	+$217K	0.06%	595

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bridgefront Capital's ATRA Position: Q2 2021 in Review

Bridgefront Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 492 shares — an estimated $177K sold.

Bridgefront Capital first reported a position in ATRA in Q1 2021 and held it in 1 quarter. The position peaked at $177K in Q1 2021. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

Bridgefront Capital reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Bridgefront Capital sold 492 Atara Biotherapeutics shares in Q2 2021, an estimated $177K.
Bridgefront Capital first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 1 quarter.
Bridgefront Capital's Atara Biotherapeutics position peaked at $177K in Q1 2021.
145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.